Oncotarget Publish about Vemurafenib resistance PTC Cells

Oncotarget is a medical journal which was established in 2010. It is published in Impact Journal and is a twice-weekly open access journal. It publishes research on all aspects of oncology and publishing sub-sessions on other aspects of the medical industry such as immunology, aging, and autophagy. On the 18th of October 2017, Oncotarget published results of Harvard medical school team who had found out that palbociclib may be used to overcome vemurafenib resistance in Papillary Thyroid Carcinoma (PTC). PTC is the most common type of thyroid cancer, and it is treated with vemurafenib. Certain mutation of cancer such as BRAFV600E has been known to resist the drug.

The same team had presented research findings that showed the cancer cells were resistant to this drug due to its loss of P16 gene which helps in prevention of multiplication of cells. The P16 gene controls cell division through the formation of a complex protein called CDK4/6 which is responsible for the replication of DNA inside the cell. The team also found that there is another gene in the cell to help in the treatment of resistance in PTC cells. This gene when combined with vemurafenib and palbociclib results in the killing of the PTC cancer cells.

Later in November 2017, the journal launched its new podcast which helps every subscriber have access to news and important research work as well as discoveries through reading the original published papers. It also allows the subscribers to access interviews with the various authors of the papers giving a more profound understanding of the topic. The podcast will also consist of a blog from Oncotarget which is for a more general audience who are not in the medical field. The blog will be written in simple language for everyone to understand and comment therefore generating discussions.

The Journal’s podcasts will be used to communicate not only medical research findings but also advantageous to both authors and researchers who want to communicate their research to pertinent stakeholders and investors. Mikhail Blagosklonny, one of the editors-in-chief stated that Oncotarget is not only a publishing journal as it is the voice of the researcher as through it one can reach a wide.

LinkedIn: https://www.linkedin.com/company/oncotarget